Up­dat­ed: Eli Lil­ly's RET drug notch­es tu­mor-ag­nos­tic ac­cel­er­at­ed ap­proval, full FDA OK in NSCLC

Eli Lil­ly has won a new ac­cel­er­at­ed ap­proval for its tu­mor-ag­nos­tic RET drug, and man­aged to con­vert an­oth­er ac­cel­er­at­ed ap­proval to a full ap­proval af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.